Our top pick for
OPKO Health, Inc is a diagnostics & research business based in the US. OPKO Health shares (OPK) are listed on the NASDAQ and all prices are listed in US Dollars. OPKO Health employs 6,096 staff and has a trailing 12-month revenue of around USD$1.2 billion.
|Latest market close||USD$4.3|
|52-week range||USD$1.1171 - USD$6.47|
|50-day moving average||USD$4.4079|
|200-day moving average||USD$4.1941|
|Wall St. target price||USD$8|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.424|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||-2.27%|
|1 month (2020-12-18)||-6.32%|
|3 months (2020-10-16)||4.3|
|6 months (2020-07-17)||-6.52%|
|1 year (2020-01-17)||175.64%|
|2 years (2019-01-17)||15.59%|
|3 years (2018-01-17)||4.47|
|5 years (2016-01-15)||8.23|
Valuing OPKO Health stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of OPKO Health's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
OPKO Health's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$65 million.
The EBITDA is a measure of a OPKO Health's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$1.2 billion|
|Gross profit TTM||USD$264.9 million|
|Return on assets TTM||-0.6%|
|Return on equity TTM||-6.99%|
|Market capitalisation||USD$3 billion|
TTM: trailing 12 months
There are currently 123.7 million OPKO Health shares held short by investors – that's known as OPKO Health's "short interest". This figure is 2.7% down from 127.1 million last month.
There are a few different ways that this level of interest in shorting OPKO Health shares can be evaluated.
OPKO Health's "short interest ratio" (SIR) is the quantity of OPKO Health shares currently shorted divided by the average quantity of OPKO Health shares traded daily (recently around 9.4 million). OPKO Health's SIR currently stands at 13.22. In other words for every 100,000 OPKO Health shares traded daily on the market, roughly 13220 shares are currently held short.
However OPKO Health's short interest can also be evaluated against the total number of OPKO Health shares, or, against the total number of tradable OPKO Health shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case OPKO Health's short interest could be expressed as 0.17% of the outstanding shares (for every 100,000 OPKO Health shares in existence, roughly 170 shares are currently held short) or 0.2877% of the tradable shares (for every 100,000 tradable OPKO Health shares, roughly 288 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against OPKO Health.
Find out more about how you can short OPKO Health stock.
We're not expecting OPKO Health to pay a dividend over the next 12 months.
Over the last 12 months, OPKO Health's shares have ranged in value from as little as $1.1171 up to $6.47. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while OPKO Health's is 1.9811. This would suggest that OPKO Health's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test. The company's Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator; and OPK88003, a once or twice weekly oxyntomodulin that is in Phase IIb trials for type 2 diabetes and obesity. It is also developing hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc.; VARUBI for chemotherapy-induced nausea and vomiting; and Factor VIIa drug for hemophilia. In addition, this segment develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, it develops, manufactures, markets, and sells pharmaceutical, nutraceutical, and veterinary products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. Additionally, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.
Everything we know about the Vacasa IPO, plus information on how to buy in.
Everything we know about the William Penn Bancorp IPO, plus information on how to buy in.
Everything we know about the Landos Biopharma Inc IPO, plus information on how to buy in.
Everything we know about the First High-School Education Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Knowlton Development Corp IPO, plus information on how to buy in.
Steps to owning and managing SASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAIL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAF, with 24-hour and historical pricing before you buy.
Steps to owning and managing RDHL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBFG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.